Detection of cancer cells using SapC-DOPS nanovesicles

Harold W. Davis¹, Nida Hussain¹ and Xiaoyang Qi¹,²*

Abstract

Unlike normal cells, cancer cells express high levels of phosphatidylserine on the extracellular leaflet of their cell membrane. Exploiting this characteristic, our lab developed a therapeutic agent that consists of the fusogenic protein, saposin C (SapC) which is embedded in dioleoylphosphatidylserine (DOPS) vesicles. These nanovesicles selectively target cancer cells and induce apoptosis. Here we review the data supporting use of SapC-DOPS to locate tumors for surgical resection or for treatment. In addition, there is important evidence suggesting that SapC-DOPS may also prove to be an effective novel cancer therapeutic reagent. Given that SapC-DOPS is easily labeled with lipophilic dyes, it has been combined with the far-red fluorescent dye, CellVue Maroon (CVM), for tumor targeting studies. We also have used contrast agents incorporated in the SapC-DOPS nanovesicles for computed tomography and magnetic resonance imaging, and review that data here. Administered intravenously, the fluorescently labeled SapC-DOPS traversed the blood–brain tumor barrier enabling identification of brain tumors. SapC-DOPS-CVM also detected a variety of other mouse tumors in vivo, rendering them observable by optical imaging using IVIS and multi-angle rotational optical imaging. Dye is detected within 30 min and remains within tumor for at least 7 days, whereas non-tumor tissues were unstained (some dye observed in the liver was transient, likely representing degradation products). Additionally, labeled SapC-DOPS ex vivo delineated tumors in human histological specimens. SapC-DOPS can also be labeled with contrast reagents for computed tomography or magnetic resonance imaging. In conclusion, labeled SapC-DOPS provides a convenient, specific, and nontoxic method for detecting tumors while concurrently offering a therapeutic benefit.

Keywords: Phosphatidylserine, Cancer, Tumor imaging, Contrast agents, Saposin C, SapC-DOPS

Background

Phosphatidylserine and cancer

Phospholipids are arranged asymmetrically in cell membranes, with neutral phospholipids on the outer leaflet and anionic phospholipids, such as phosphatidylethanolamine and phosphatidylserine (PS), located primarily on the inner leaflet of the membrane [1–3]. A translocase, the flippase complex, selective for PE and PS, is an ATP-dependent pump that catalyzes rapid inward migration of these phospholipids [1] to maintain this configuration. Collapse of this asymmetry is an early process in apoptosis that results in the translocation of PS to the exterior of the cell. In a normal cell undergoing apoptosis, the externalized PS serves as a trigger for phagocytes, particularly macrophages, to engulf the cell, minimizing inflammation [4, 5].

Although cancer cells and their associated tumor vasculature also exhibit a high level of PS on the outer leaflet [6–9], this externalized phospholipid is not associated with apoptosis. Critically, the mechanisms by which cancer cells actually resist phagocytosis remain incompletely understood [9]. Compared with non-malignant cells, expression of PS on the cell surface is a consistent marker of malignancy in both primary and metastatic cell lines [6–12]. In their study focused on difficult-to-treat primary cancers, including metastatic melanoma, glioblastoma, and metastatic lesions, Riedl et al. [11] demonstrated the specificity of abundant externalized PS for malignant tumors. While virtually all cancer cells exhibit high external PS compared with normal cells, the quantity of surface PS varies widely among different cancer cells, even of the
same type [10, 12]. The increase in surface PS has led to the use of a number of proteins or peptides that bind to PS to study apoptotic and tumor cells [2, 4, 13]; among these are annexin A5 (ANXA5), an endogenous anticoagulant protein, and lactadherin (MFGE8) [2, 14], a major glycoprotein in milk that promotes cellular adhesion. Additionally, monoclonal antibodies to PS have been generated that demonstrate anti-tumor activity [6, 15]. All of these have been conjugated to a number of markers to detect the location of PS.

In this review, we discuss Saposin C-Dioleoylphosphatidylserine (SapC-DOPS), a stable nanovesicle that specifically binds PS but, importantly, also has demonstrated therapeutic properties against a variety of cancer types. Given the specificity of SapC-DOPS for cells that have undergone neoplastic transformation and the resultant enhancement seen on imaging studies owing to the externalization of PS on cancer cells, we review this new paradigm for improved diagnosis and early detection of malignancy that may overcome some of the limitations of current imaging related to the cancer’s type and site or to other underlying medical conditions (e.g., diabetes and kidney disease).

**SapC-DOPS**

Saposin C (SapC) is a small, fusogenic glycoprotein that is remarkably heat-stable and protease-resistant [16–19]. While SapC itself is non-enzymatic, it is an activator of lysosomal enzymes, particularly acid sphingomyelinase and acid beta-glucosidase, which catalyze the breakdown of sphingomyelin and glucosylceramide into phosphocholine and ceramide, and glucose and ceramide, respectively [20–22]. Although the precise mechanism is unclear, this increase in ceramide levels may result in cell death, as ceramide has been previously implicated in apoptosis [23], possibly through the actions of caspases [24]. In order for SapC to activate these enzymes, it must bind the PS of the intracellular vesicles’ membranes. In vitro, at low pH, SapC and dioleoylphosphatidylserine (DOPS) will spontaneously form nanovesicles with a mean diameter of approximately 200 nm (Fig. 1). The amino- and carboxyl termini of SapC are amphipathic helices that insert into the lipid bilayer, while the middle region is exposed to solvent. Conformational changes of SapC induced by PS interaction suggest a reorientation of the functional helical domains [25]. Importantly, the cytotoxicity of SapC-DOPS positively correlates with the level of surface PS: the higher the external PS, the more effectively SapC-DOPS [10, 12] will bind the cell and trigger the ceramide cascade, ultimately resulting in apoptosis (Fig. 2).

**Main Text**

**Use of SapC-DOPS as a tumor detection agent**

**Histological sections**

In our lab, the role of PS as a tumor marker has been validated repeatedly for a variety of cancer types [10, 24, 26–30]. In particular, the targeting of PS by SapC-DOPS was demonstrated to be a novel method to achieve accurate and effective identification of cancer cells. The validation of PS as a reliable tumor marker, coupled with the high affinity of SapC-DOPS for PS on a variety of cancer cell surfaces, provides a promising advancement for accurate detection of several cancer types.

The lipophilic properties of SapC-DOPS make it an ideal carrier of detection moieties, such as fluorescent markers or clinically applicable contrast agents (Fig. 3). Experiments coupling SapC-DOPS to the far-red fluorescent probe CellVue Maroon (CVM) have been performed to distinguish neoplastic tumor regions on histologic slides and individual patient-derived neoplastic cell lines, as well as in vivo [10, 24, 26–28, 31]. In several studies showing the specificity of this reagent, SapC-DOPS-CVM was internalized by live tumor cells but not normal cells, clearly
delineating the tumor in tissue slices. A caveat of using histological slides is that their generation requires slicing the cells, so that SapC-DOPS or other PS detection agents will bind to PS on both the exterior and interior of the membrane. However, fluorescently labeled SapC-DOPS can be used with flow cytometry to distinguish only the externalized PS.

Of particular interest is the role of SapC-DOPS in detecting cancers that pose diagnostic challenges because of the tumor site or the intrinsic properties of the malignancy itself, by targeting surface PS of cancer cells and tumor vessels. Such cancers include glioblastoma and pancreatic adenocarcinoma, each of which carries a devastating prognosis despite years of diagnostic and therapeutic research.

**Fluorescent SapC-DOPS detection in mice**

Previous studies have taken in vitro data of fluorescently labeled SapC-DOPS a step further by evaluating diagnostic efficacy in vivo using mouse models. In one such study, mice bearing human neuroblastoma xenografts were injected intravenously with four different reagents: (1) SapC-DOPS conjugated to CVM, (2) unconjugated SapC and CVM, (3) DOPS and CVM, or (4) PBS alone [24]. The mice then underwent optical imaging at time intervals ranging from 0 to 48 h post-injection. The SapC-DOPS-CVM fluorescent signal was diffuse between 0 and 5 h, and had accumulated specifically within the tumor region by 24 h, persisting for up to 100 h. However, there was no fluorescence signal when uncoupled SapC was administered with DOPS-CVM [24]. Similar results were
demonstrated by Kaimal et al. [29] in their mouse xenograft models of pancreatic adenocarcinoma and neuroblastoma and a murine rhabdomyosarcoma model. These studies demonstrated the specificity of SapC-DOPS for cells that have undergone neoplastic transformation, with the consequent externalization of PS. As such, this is a new paradigm for improved diagnosis and early detection of malignancy.

In multi-angle rotational optical imaging (MAROI) to detect SapC-DOPS-CVM in mice [32], we used a rotational bed to obtain the in vivo image. Analysis of the MAROI signal curve provided multispectral and multimodal data derived from complete rotational coverage. We confirmed that optimal imaging depended on correct orientation during positioning; the fluorescence intensity decreased by as much as 9–12 % with each 10° of movement. Use of anatomical landmarks and concurrent X-ray imaging achieved both in vivo localization of the tumor and quantitation of fluorescent marker intensity. These findings can then be used in longitudinal studies to correlate fluorescent signal distribution directly with mapping of tumor location.

**Impediments to clinical detection of malignancy using multimodality imaging**

Among the factors considered when determining an optimal treatment plan for patients diagnosed with cancer, especially important are the size and location of the primary tumor and the extent of metastatic disease, if present. To define these characteristics and facilitate treatment, effective imaging modalities currently available include computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging (MRI). Each modality can help define cancer staging and diagnosis, but can also be limited in its effectiveness, depending on the type and site of the cancer or the patient’s underlying medical conditions. When such limitations exist, invasive procedures or a combination of diverse imaging techniques may be needed to make a definitive diagnosis; this can be both time-consuming and cost prohibitive (see Table 1).

CT has played a pivotal role in both diagnosis and staging of malignancy for several years. Although CT has been successful in upstaging many cancers at the time of diagnosis to improve treatment outcomes, several limitations prevent its universal applicability in cancer diagnosis, particularly in cases of local, microscopic disease spread. In a study of 957 lymph nodes evaluated from patients with head and neck cancers, Don et al. [33] found that 20 % of malignant lymph nodes had extracapsular spread; almost one third of these nodes were smaller than 10 mm, which is the size cut-off used to define pathological adenopathy on radiographic review. In addition, central necrosis, a common characteristic used to identify malignant lymph nodes by CT, were found primarily in lymph nodes that were 20 mm or larger, suggesting that central necrosis is a late event in metastatic adenopathy. Such findings suggest a deficiency in our ability to detect metastatic disease early in its course [33].

In contrast with CT and MRI, detection by PET imaging has proven superior for regional nodal and distant metastases, but inferior for several primary malignancies [34]. Moreover, PET has very poor spatial resolution, limiting accurate biopsy because of poor localization of the potential malignancy. While this problem can be offset in part by combined PET-CT scanning, defects in registration between the signals can still pose problems with tumor localization [34].

As such, currently available imaging modalities present shortcomings in our ability to detect occult spread of malignancy, which inevitably leads to delays in diagnosis of metastatic disease until it has spread more widely. At that point, few treatment options may remain. Such studies highlight the need for sensitive imaging techniques that focus on specifically revealing malignant cells, rather than probing tentative neoplastic properties of lymph nodes that may imply, but are not always specific for, malignancy.

**Table 1** Comparison of non-invasive imaging procedures for cancer detection

| Imaging method                      | Benefits                                                                 | Limitations                                                                 |
|-------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Optical Imaging                     | Fluorescently labeled probes may be sensitive and specific                | Limited depth, may be too specific, may require a visit to inject the probe with a follow-up visit to detect where it binds |
| Computed Tomography (CT)            | Fast, highly detailed                                                    | Exposure to ionizing radiation, may not be able to differentiate tumor from other lesions, may not detect small tumors, may require potentially toxic contrast agents, not ideal modality for brain tumor detection |
| Magnetic Resonance Imaging (MRI)    | Used for detection of brain tumors, no radiation exposure for patient    | Prolonged acquisition time, metal implants preclude this technique, requires potentially toxic contrast agents |
| Positron Emission Tomography (PET)  | Better than CT or MRI for nodal or distant metastases                     | Poor special resolution, inferior for detection of primary tumors, cannot detect brain tumors, use of FDG impacted in diabetics, exposure to ionizing radiation |
Detection of intracranial neoplasms, such as glioblastoma multiforme, also poses a diagnostic challenge by currently available imaging techniques. PET imaging, for example, relies on underlying tissue metabolism to detect malignancy, given that neoplastic cells have increased metabolic activity compared with normal tissue. Non-malignant brain tissue, however, has metabolic activity comparable to tumors found in areas outside of the brain. Because intracranial neoplasms cannot be accurately identified on PET imaging, a second mode of imaging is needed to detect either primary or metastatic disease in the brain. Similarly, a CT of the brain can delineate brain lesions but often cannot definitively distinguish neoplastic tumors from other causes of brain lesions, including infections or demyelinating diseases. Therefore, detection of intracranial malignancy currently relies on MRI for evaluation and characterization. Such studies, however, require prolonged acquisition time, which can cause increased motion artifact and result in poor image quality unless the patient is sedated, as for pediatric patients, which increases patient risk.

Beyond accurate detection of malignancy, limitations in current imaging modalities also relate to any underlying medical conditions of the patient. For example, CT imaging often requires an intravenous contrast agent. Contrast can be particularly nephrotoxic for patients with acute or chronic kidney disease. This comorbidity is common in patients at the time of cancer diagnosis because of poor oral intake and prolonged cachexia, and can also be a frequent consequence of several chemotherapeutic regimens. Thus, contrast-enhanced CT imaging is commonly avoided in patients with underlying kidney disease. Similar caution must be taken when using gadolinium contrast for MRI in patients with kidney disease because of the possibility of adverse outcomes, such as nephrogenic systemic sclerosis, which carries a high rate of morbidity and mortality. Limitations in PET imaging occur in diabetic patients, because blood glucose levels can significantly impact tumor uptake of fluorodeoxyglucose (FDG), the agent used to detect malignancy. In these cases, FDG and glucose compete for glucose transport and phosphorylation [35]. Guidelines currently require both tight glycemic control (i.e., glucose levels below 200 mg/dL) before PET imaging and that patients abstain from all glucose-containing food and drink for at least 6 h prior to the study. However, these restrictions have often proven difficult to achieve, thus compromising imaging quality and accuracy. Advances in combined PET/CT [36] and PET/MRI [37] have solved some of these problems. However, the toxicity of contrast agents and their inability to cross the blood–brain barrier limit their effectiveness and demonstrate the necessity for a diagnostic agent with limited side effects, few clinical restrictions, and enhanced specificity for neoplastic cells.

Detection of malignancy using SapC-DOPS in preclinical studies

To improve MRI sensitivity, shorten scanning time, and improve safety, we have used SapC-DOPS as a carrier for contrast agents. The method of Bogdanov et al. [38] was implemented to encapsulate ferumoxtran-10, an ultra-small super-paramagnetic iron oxide (USPIO) contrast agent, into SapC-DOPS vesicles. The resulting SapC-DOPS-USPIO was used with MRI to detect tumors in mice [29]. The T2 relaxation time (i.e., time for the transverse magnetization to fall to approximately 37 % of its initial value after magnetization) of subcutaneous xenografts of neuroblastomas or pancreatic tumors was decreased by SapC-DOPS-USPIO, thus indicating the uptake of the agent by tumors. This allowed specific detection of the malignancy (Fig. 4a).

Additionally, we incorporated the paramagnetic contrast agent, gadolinium, into SapC-DOPS vesicles by using the lipophilic gadolinium chelate, gadolinium-DTPA-bis (stearylamine) [39]. These vesicles produced a 9 % increase in the longitudinal relaxation rate (R1) of orthotopic glioblastoma multiforme tumors in mice within 10 h post-injection, but only minimal changes in normal brain tissue; again this demonstrated improved specificity of tumor detection.

We have recently used a phenol-substituted lipophilic dye to label SapC-DOPS with 124I, a positron emitter. We then used this labeled SapC-DOPS for PET imaging. As shown in Fig. 4b we were able to selectively enhance the intracranial glioblastomas with PET scanning [40]. Concurrent studies with SapC-DOPS labeled with 125I instead of 124I indicated that SapC-DOPS specifically targeted the tumor, although some label was detected in the liver and spleen, likely disposal routes.

These studies indicate the ability of SapC-DOPS to transverse the blood brain barrier without requiring either alteration of the barrier or direct intracranial administration of the agent [12]. This suggests a potential role for SapC-DOPS in improving the safety and convenience of detecting (and treating) intracranial neoplasms.

The pharmacologic safety of SapC-DOPS has been evaluated in mice at 12× the typical therapeutic dose of 4 mg/kg of Sap C and 2 mg/kg of DOPS [24]. Even at these levels, no acute toxicity or weight loss was demonstrated with administration. Furthermore, histological examination of vital organs (i.e., lung, liver, spleen, kidney, heart, brain) revealed neither damage nor toxic changes. Chronic toxicity studies were also performed with injection of 2× therapeutic concentrations of SapC-DOPS weekly for 5 weeks. Again, these studies demonstrated no significant toxicity on histological review of the vital organs listed above [24]. In comparison, the contrast agents currently used for image enhancement during CT and MRI scanning can place patients at risk for kidney damage or systemic disease. Beyond the pharmacologic safety evidence,
we compared survival data for mice with pancreatic tumors treated with SapC-DOPS versus control groups. Mice treated with SapC-DOPS lived significantly longer compared with untreated control groups: specifically, all control mice had died by 23 weeks after treatment, while 4 of the 6 SapC-DOPS-treated mice were still alive [10]. Similar results were obtained with a brain tumor model [28]. Mice bearing orthotopic glioblastoma multiforme that were treated with DOPS alone all died within 20 days. However, 25% of those treated with SapC-DOPS survived at least 350 days. In addition, the tumors were smaller in the SapC-DOPS treated mice. Again, these studies provide pre-clinical data to support the safety of systemic SapC-DOPS administration for diagnostic and therapeutic purposes. Although there is some therapeutic value of SapC-DOPS with the dose that would be injected for diagnostic purposes, multiple doses are generally given to shrink tumors. Additionally, as SapC-DOPS is a nanovesicle it can be loaded with radioisotopes or chemotherapeutic drugs to provide further benefit.

Conclusions
Our data indicate that the novel and PS-targeted nanovesicle, SapC-DOPS, can be used for exposure of hard to detect malignancies, whether due to size or location. Although further studies are required, our preclinical studies suggest that the tumor-selective nanovesicles may greatly contribute to improving the precision of early cancer diagnosis. In addition, SapC-DOPS may have a therapeutic benefit and be used as a “theranostic” compound. Ongoing studies are to provide support for the inclusion of SapC-DOPS in the battery of tests conducted by oncologists to enhance the accuracy and sensitivity of tumor diagnosis.

Ethics approval
The ethical approval for the animal studies described in this review are provided in the original publications.

Abbreviations
CT: computed tomography; CVM: CellVue Maroon; FDG: fluorodeoxyglucose; MAROI: multi-angle rotational optical imaging; MRI: magnetic resonance imaging; PET: positron emission tomography; PS: phosphatidylserine; SapC-DOPS: saposin-C-Dioleophosphatidylserine; USPIO: ultra-small super-paramagnetic iron oxide.

Competing interests
Xiaoyang Qi, Ph.D. is listed as an inventor on the patent for the technology (SapC-DOPS) that is the subject of this research. Consistent with current Cincinnati Children’s Hospital Medical Center policies, the development and commercialization of this technology has been licensed to Bexion Pharmaceuticals, LLC, in which Dr. Qi holds a minor (<5%) equity interest. This work was supported in part by R01CA158372-01A0 (to X. Qi), R21NS095047-01A0 (to X. Qi), Brain Tumor Center Research Funds and Hematology-Oncology Programmatic Support from University of Cincinnati College of Medicine (to X. Qi), and New Drug State Key Project Grant Number 009ZX09102-205 (to X. Qi).

Authors’ contributions
XQ conceived of this review article. HWD and NH participated in its design and helped to draft the manuscript. All authors read and approved the final manuscript.
References

1. Bevers EM, Comfurius P, Zwaal RF. Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. Lupus. 1996;5:480–7.

2. Kay JG, Grinstein S. Sensing phosphatidylserine in cellular membranes. Sensors (Basel). 2011;11:1744–55.

3. Williamson P, Schlegel RA. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Mol Membr Biol. 1994;11:199–216.

4. Blankenberg FG, Strauss HW. Recent advances in the molecular imaging of programmed cell death: part I–pathophysiology and radiotracers. J Nucl Med. 2012;53:659–62.

5. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002;109:41–50.

6. Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessel enhances the antitumor effect of doctaxel on human breast tumors in mice. Cancer Res. 2005; 65:4408–16.

7. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:132–40.

8. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys. 2002;54:179–84.

9. Utsugi T, Schroit AJ, Connor J, Bucana CD, Fidler U. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res. 1991;51:3062–6.

10. Chu Z, Abu-Baker S, Palascak MB, Ahmad SA, Franco RS, Qi X. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One. 2013;8:e75507.

11. Riedl S, Rinner B, Asslaber M, Schader H, Walzer S, Novak A, Lohner K, Zwygird D. In search of a novel target–phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta. 2011;1808:2638–45.

12. Wolof J, Chu Z, Mathyasurya H, Meisen WH, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, et al. Systemic delivery of SapC-DOPS contains antiangiogenic and anti-tumor effects against glioblastoma. Mol Ther. 2013;21:1517–25.

13. Blankenberg FG, Strauss HW. Recent advances in the molecular imaging of programmed cell death: Part II–non-probe-based MRI, ultrasound, and optical clinical imaging techniques. J Nucl Med. 2013;54:1–4.

14. Taylor MR, Couto JR, Scallan CD, Ceranic RL, Peterson JA. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Ang-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 1997;16:681–9.

15. Bukaj E, Preto F, Neti D. Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids. Invest New Drugs. 2015;33:791–800.

16. Kishimoto Y, Hiraiai M, O’Brien JS. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res. 1992;33:1255–67.

17. Qi X, Leonova T, Grabowski GA. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem. 1994;269:16746–53.

18. Vaccaro AM, Salvioni R, Barca A, Tatti M, Ciuffoni F, Salvioli R, Serafino A, Barca A. Saposin C induces pH-dependent destabilization and fusion of phosphatidylserine-containing vesicles. FEBS Lett. 1994;349:181–6.

19. Taha TA, Mullen TD, Obeid LM. A house divided: ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta. 2006;1759:2027–36.

20. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, Cripe TP. Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res. 2009;15:5840–51.

21. Qi X, Grabowski GA. Differential membrane interactions of saposins A and C: implications for the functional specificity. J Biol Chem. 2001;276:27010–7.

22. Abu-Baker S, Chu Z, Stevens AM, Li J, Qi X. Cytotoxicity and selectivity in skin cancer by SapC-DOPS nanovesicles. J Cancer Ther. 2012;3:321–6.

23. Blanco VM, Chu Z, Vallabhapurapu SD, Sulaiman MK, Kaur B, Rioux O, Warnick RE, Franco RS, Qi X. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget. 2014;5:7105–18.

24. Blanco VM, Curry R, Qi X. SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma. Oncoscience. 2015;2102–10.

25. Kaimal V, Chu Z, Mahller YY, Papahadjopoulos-Sternberg B, Cripe TP, Holland SK, Qi X. Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol. 2011;13:886–97.

26. Zhao S, Chu Z, Blanco VM, Nie Y, Hou Y, Qi X. SapC-DOPS nanovesicles as targeted therapy for lung cancer. Mol Cancer Ther. 2015;14:491–8.

27. Zappacosta F, Amoresano A, Pucci P. Structural analysis of saposin C and B. J Biol Chem. 2001;276:22816–23.

28. Blanco VM, Chu Z, Vallabhapurapu SD, Sulaiman MK, Kaur B, Rioux O, Warnick RE, Franco RS, Qi X. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget. 2014;5:7105–18.

29. Blanco VM, Curry R, Qi X. SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma. Oncoscience. 2015;2:102–10.

30. Bujak E, Pretto F, Neri D. Generation and tumor recognition properties of SapC-DOPS nanovesicles. Proc Natl Acad Sci USA. 2004;101:7355–60.

31. Blankenberg FG, Strauss HW. Recent advances in the molecular imaging of programmed cell death: part I–pathophysiology and radiotracers. J Nucl Med. 2012;53:659–62.

32. Blanco VM, Chu Z, Vallabhapurapu SD, Sulaiman MK, Kaur B, Rioux O, Warnick RE, Franco RS, Qi X. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget. 2014;5:7105–18.

33. Blankenberg FG, Strauss HW. Recent advances in the molecular imaging of programmed cell death: Part II–non-probe-based MRI, ultrasound, and optical clinical imaging techniques. J Nucl Med. 2013;54:1–4.

34. Taylor MR, Couto JR, Scallan CD, Ceranic RL, Peterson JA. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Ang-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 1997;16:681–9.

35. Bukaj E, Preto F, Neti D. Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids. Invest New Drugs. 2015;33:791–800.

36. Kishimoto Y, Hiraiai M, O’Brien JS. Saposins: structure, function, distribution, and molecular genetics. J Lipid Res. 1992;33:1255–67.

37. Qi X, Leonova T, Grabowski GA. Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem. 1994;269:16746–53.

38. Vaccaro AM, Salvioni R, Barca A, Tatti M, Ciuffoni F, Maras B, Scilliano R, Zappacosta F, Amoresano A, Pucci P. Structural analysis of saposin C and B. Complete localization of disulfide bridges. J Biol Chem. 1995;270:9920–8.

39. Wang Y, Grabowski GA, Qi X. Phospholipid vesicle fusion induced by saposin C. Arch Biochem Biophys. 2003;415:45–53.

40. Koler T, Sandhoff K. Lysosomal degradation of membrane lipids. FEBS Lett. 2010;584:1700–12.

41. Qi X, Chu Z. Fusogenic domain and lysines in saposin C. Arch Biochem Biophys. 2004;424:210–8.